CLSI M24S
Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes
CLSI M24S provides the latest breakpoint and quality control tables for use with CLSI document M24, ensuring accurate and standardized susceptibility testing of Mycobacterium tuberculosis complex (MTBC), clinically significant mycobacteria, Nocardia spp., and other aerobic actinomycetes.
This edition includes critical updates to breakpoints and quality control parameters, reflecting the most current scientific and clinical data.
{{FormatPrice(currentPrice)}}
Free
{{FormatPrice(nonMemberPrice)}} List PriceClinical and Laboratory Standards Institute document M24S—Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24. The data in the tables are valid only when the methodology in CLSI document M24 is followed.
This document replaces the previous edition of the approved document, M62-Ed1, published in 2018. This supplement contains the most current information and serves as a means to notify laboratories of important changes that occur between published editions of CLSI document M24. Several changes were made in this edition.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This edition of the document has been corrected, read the full correction notice here.
Clinical and Laboratory Standards Institute document M24S—Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24. The data in the tables are valid only when the methodology in CLSI document M24 is followed.
This document replaces the previous edition of the approved document, M62-Ed1, published in 2018. This supplement contains the most current information and serves as a means to notify laboratories of important changes that occur between published editions of CLSI document M24. Several changes were made in this edition.
The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.
This edition of the document has been corrected, read the full correction notice here.